{
    "clinical_study": {
        "@rank": "122840", 
        "acronym": "UTOPIA", 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the impact of pharmacogenomic aspects of drug\n      metabolism on the measurement of drug and drug metabolites on urine drug testing (UDT)."
        }, 
        "brief_title": "Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Urine Toxicology", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Able to provide written informed consent\n\n          -  Pharmacogenomic testing within the last 60 days\n\n          -  Planned UDT\n\n        Exclusion Criteria:\n\n          -  Subject has chronic renal dysfunction, Chronic Kidney Disease Stage 4 or 5\n\n          -  Subject has a history of abnormal hepatic function within the last 2 years (INR >1.2\n             not attributable to anticoagulant medications, AST or ALT >1.5x normal, or suspected\n             cirrhosis)\n\n          -  Subject has a history of malabsorption (short gut syndrome);\n\n          -  Subject has a history of any gastric or small bowel surgery;\n\n          -  Subject is currently hospitalized;\n\n          -  Subject is currently receiving intravenous medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male and female subjects who are considered candidates for UDT."
            }
        }, 
        "enrollment": {
            "#text": "200000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096172", 
            "org_study_id": "2013-002"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 21, 2014", 
        "number_of_groups": "1", 
        "official_title": "Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Occurrence of genetically-determined abnormal metabolism of drugs tested with UDT, classified as genetic effects on metabolism (GEM) + for rapid metabolizers, GEM 0 for normal metabolizers, and GEM - for slow metabolizers.", 
            "measure": "Influence of CYP450 drug metabolism on quantitative UDT", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096172"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of illicit drugs detected on UDT and the GEM classification associated with these medications", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Non-prescribed drugs detected on UDT and the GEM classification associated with these medications", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "False positive immunoassay results, defined as positive immunoassay concurrent with negative quantitative testing", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Frequency of target drug regimen changes by the treating physician due to pharmacogenomic test results", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Frequency of illicit drug changes by the subject due to UDT results, as observed at the time of repeat UDT", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Frequency of non-prescribed drug changes by the subject due to UDT results, as detected at the time of repeat UDT", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Renaissance RX", 
        "sponsors": {
            "collaborator": {
                "agency": "Syntactx", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Renaissance RX", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "24 Months", 
        "verification_date": "March 2014"
    }
}